AZIYO BIOLOGICS(AZYO) - 2024 Q4 - Annual Report

Product Development and Innovation - Elutia's EluPro is the only drug-eluting biomatrix in the U.S. for implantable electronic device protection, addressing complications such as infection and device migration[32][33]. - Elutia's innovative DEB technology is expected to redefine patient outcomes and procedural success in implantable device surgeries[42]. - EluPro received FDA clearance in June 2024, with ongoing stability studies to support a Special 510(k) filing for additional sizes[62]. - Elutia's SimpliDerm product, utilizing human-based hydrated acellular dermal matrix, aims to enhance tissue incorporation and reduce inflammation compared to other matrices[34]. - SimpliDerm is designed to improve biocompatibility and tissue integration, utilizing patented cell removal technology to maintain the extracellular matrix's integrity[90]. - SimpliDermRM is being developed to address post-operative infections in breast reconstruction, which affect over 10% of patients, with complication rates for implant-based reconstruction ranging from 26% to 31%[91][92]. - SimpliDerm's clinical data supports its differentiation in the market, with testing indicating it has a structurally intact matrix closest to native human dermis compared to alternatives[98][99]. Market Opportunities and Strategy - The company estimates over 700,000 surgical procedures annually in the U.S. involve the implantation of medical devices, driven by technological advances and an aging population[28]. - Elutia's growth strategy focuses on increasing penetration in Device Protection and Women's Health markets, which represent a combined market opportunity of over $1 billion in the U.S.[44]. - The commercial approach includes a partnership with Boston Scientific, providing access to approximately 900 sales representatives to expand market penetration[64]. - The use of acellular dermal matrices in breast reconstruction surgery in the U.S. grew by 29% in 2022 compared to 2020, representing a market of approximately $500 million[83]. - The company has established commercial relationships with major medical device companies, leveraging approximately 1,100 sales representatives to enhance market penetration[46]. Financial Performance and Challenges - The company reported net losses of $53.9 million and $37.7 million for the years ended December 31, 2024, and 2023, respectively[187]. - The accumulated deficit as of December 31, 2024, was $229.6 million, raising substantial doubt regarding the company's ability to continue as a going concern[188]. - The company has incurred operating losses and expects to continue doing so in the near term, impacting its financial position[187]. - The company is actively seeking additional funding to support operations and pursue growth strategies, which may include issuing common stock or asset sales[190]. - The company faces significant litigation risks related to product recalls, with 66 lawsuits outstanding for FiberCel Recall and 15 for VBM Recall as of December 31, 2024[204]. Regulatory Environment - The company’s products are subject to extensive regulation by the FDA, with medical devices classified into three categories based on risk, impacting the marketing and approval processes[129][130]. - The FDA can impose sanctions for non-compliance, including product recalls and withdrawal of marketing approvals[142]. - The company no longer maintains its CE mark for cardiovascular products in the EU, which expired on May 23, 2024[146]. - International sales of medical devices require compliance with varying regulatory requirements across different countries[145]. Product Sales and Distribution - Sales in the U.S. accounted for over 96% of the company's net sales in 2024, with international sales ceasing after May 2024 due to regulatory changes[111]. - The company signed a lease for 26,598 square feet in Gaithersburg, Maryland, to develop in-house production capabilities for SimpliDerm, expected to be operational by Q3 2025[116]. - The company has a direct sales force and independent agents, with 11 direct representatives and 31 independent agents focused on expanding market access[37]. Legal and Liability Issues - The company recorded a total estimated contingent liability of $20.4 million related to FiberCel and VBM lawsuits, with $15.9 million for FiberCel and $4.5 million for VBM as of December 31, 2024[200]. - As of December 31, 2024, the company has exhausted its insurance coverage for FiberCel liability, leaving a contingent liability of $15.9 million entirely as its financial responsibility[208]. - The company must maintain a minimum liquidity of $5.0 million or the sum of the operating burn for the two prior consecutive fiscal quarters, as per the financial covenants of the SWK Loan Facility[195]. Operational Risks and Dependencies - The company faces risks related to its reliance on a limited number of third-party suppliers, particularly Cook, which supplies essential biomaterials for its products[226]. - The company has significant expansion capabilities in its in-house manufacturing facility located in Roswell, Georgia, and relies on Cook Biotech as its sole porcine tissue supplier[114]. - The company acknowledges that current volatility in capital and credit markets could impede access to financing, potentially affecting its operational and strategic decisions[216].